Compile Data Set for Download or QSAR
Report error Found 131 of Enz. Inhib. data with enzyme = 'Epidermal growth factor receptor' and Substrate = 'Poly(E:Y)'
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM3084(6-(2,6-dichlorophenyl)-2-[(4-hydroxyphenyl)amino]-...)
Affinity DataAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM3088(ethyl 3-{[6-(2,6-dichlorophenyl)-8-methyl-7-oxo-7H...)
Affinity DataAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM3595(4-N-(3-bromophenyl)-7-N,7-N-dimethylpyrido[4,3-d]p...)
Affinity DataIC50: 0.0900nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM3594(4-N-(3-bromophenyl)-7-N-methylpyrido[4,3-d]pyrimid...)
Affinity DataIC50: 0.130nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM4780(N-[4-(3-Bromoanilino)pyrido[3,4-d]pyrimidin-6-yl]-...)
Affinity DataIC50: 0.170nMpH: 7.4 T: 2°CAssay Description:Enzyme assays for IC50 determinations were performed in 96-well filter plates. IC50 is the inhibitor concentration which inhibits 50% of kinase activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM3646(2-({4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidin...)
Affinity DataIC50: 0.240nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM3671(4-[(3-Bromophenyl)amino]-7-[(3-carboxypropyl)amino...)
Affinity DataIC50: 0.280nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM3624(N-(3-bromophenyl)-1-methyl-1H-pyrazolo[4,3-g]quina...)
Affinity DataIC50: 0.370nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM4791((2E)-3-({4-[(3-bromophenyl)amino]quinazolin-6-yl}c...)
Affinity DataIC50: 0.370nMpH: 7.4 T: 2°CAssay Description:Enzyme assays for IC50 determinations were performed in 96-well filter plates. IC50 is the inhibitor concentration which inhibits 50% of kinase activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM4808(N-(3-Bromophenyl)-6-(vinylsulfonyl)pyrido[3,4-d]py...)
Affinity DataIC50: 0.430nMAssay Description:Enzyme assays for IC50 determinations were performed in 96-well filter plates. IC50 is the inhibitor concentration which inhibits 50% of kinase activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM3582(N-(3-bromophenyl)-1H-pyrazolo[4,3-g]quinazolin-5-a...)
Affinity DataIC50: 0.440nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM3583(Pyrroloquinazoline deriv. 3a | Anilinopyrimidine d...)
Affinity DataIC50: 0.440nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM4798((2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-N...)
Affinity DataIC50: 0.440nMAssay Description:Enzyme assays for IC50 determinations were performed in 96-well filter plates. IC50 is the inhibitor concentration which inhibits 50% of kinase activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM4783((2E)-N-{4-[(3-bromophenyl)amino]pyrido[3,4-d]pyrim...)
Affinity DataIC50: 0.5nMpH: 7.4 T: 2°CAssay Description:Enzyme assays for IC50 determinations were performed in 96-well filter plates. IC50 is the inhibitor concentration which inhibits 50% of kinase activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM3667(4-[(3-Bromophenyl)amino]-7-[[3-(imidazol-1-yl)prop...)
Affinity DataIC50: 0.510nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM4596((2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}bu...)
Affinity DataIC50: 0.550nMpH: 7.4 T: 2°CAssay Description:Enzyme assays for IC50 determinations were performed in 96-well filter plates. IC50 is the inhibitor concentration which inhibits 50% of kinase activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM4802((2E)-N1-[4-(3-Bromoanilino)pyrido[3,4-d]pyrimidin-...)
Affinity DataIC50: 0.560nMAssay Description:Enzyme assays for IC50 determinations were performed in 96-well filter plates. IC50 is the inhibitor concentration which inhibits 50% of kinase activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM3670(4-[(3-Bromophenyl)amino]-7-[(2-carboxyethyl)amino]...)
Affinity DataIC50: 0.610nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM4804((2E)-N1-[4-(3-Chloro-4-fluoroanilino)pyrido[3,4-d]...)
Affinity DataIC50: 0.610nMAssay Description:Enzyme assays for IC50 determinations were performed in 96-well filter plates. IC50 is the inhibitor concentration which inhibits 50% of kinase activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM4785((2Z)-N-[4-(3-Bromoanilino)-6-pyrido[3,4-d]pyrimidi...)
Affinity DataIC50: 0.690nMpH: 7.4 T: 2°CAssay Description:Enzyme assays for IC50 determinations were performed in 96-well filter plates. IC50 is the inhibitor concentration which inhibits 50% of kinase activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM4567(CHEMBL285063 | N-{4-[(3-bromophenyl)amino]quinazol...)
Affinity DataIC50: 0.700nMpH: 7.4 T: 2°CAssay Description:Enzyme assays for IC50 determinations were performed in 96-well filter plates. IC50 is the inhibitor concentration which inhibits 50% of kinase activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2005
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM3642(5-[(3-bromophenyl)amino]-3-[[N-(carboxymethyl)-N-m...)
Affinity DataIC50: 0.720nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM4800((2E)-N1-[4-(3-Bromoanilino)pyrido[3,4-d]pyrimidin-...)
Affinity DataIC50: 0.730nMAssay Description:Enzyme assays for IC50 determinations were performed in 96-well filter plates. IC50 is the inhibitor concentration which inhibits 50% of kinase activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM3662(4-[3-({4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimi...)
Affinity DataIC50: 0.740nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM4805(N-{4-[(3-bromophenyl)amino]pyrido[3,4-d]pyrimidin-...)
Affinity DataIC50: 0.760nMAssay Description:Enzyme assays for IC50 determinations were performed in 96-well filter plates. IC50 is the inhibitor concentration which inhibits 50% of kinase activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM3630(N-(3-bromophenyl)-8-methyl-8H-pyrrolo[3,2-g]quinaz...)
Affinity DataIC50: 0.800nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM4801((2E)-N-{4-[(3-bromophenyl)amino]pyrido[3,4-d]pyrim...)
Affinity DataIC50: 0.810nMAssay Description:Enzyme assays for IC50 determinations were performed in 96-well filter plates. IC50 is the inhibitor concentration which inhibits 50% of kinase activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM3668(4-N-(3-bromophenyl)-7-N-[2-(1H-imidazol-4-yl)ethyl...)
Affinity DataIC50: 0.910nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM4777(N-{4-[(3-bromophenyl)amino]pyrido[3,4-d]pyrimidin-...)
Affinity DataIC50: 0.910nMpH: 7.4 T: 2°CAssay Description:Enzyme assays for IC50 determinations were performed in 96-well filter plates. IC50 is the inhibitor concentration which inhibits 50% of kinase activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM3648(3-({4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidin...)
Affinity DataIC50: 0.920nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM4787((2E)-N-[4-(3-Bromoanilino)pyrido[3,4-d]pyrimidin-6...)
Affinity DataIC50: 1.10nMpH: 7.4 T: 2°CAssay Description:Enzyme assays for IC50 determinations were performed in 96-well filter plates. IC50 is the inhibitor concentration which inhibits 50% of kinase activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM4799((2E)-N-{4-[(3-bromophenyl)amino]pyrido[3,4-d]pyrim...)
Affinity DataIC50: 1.10nMAssay Description:Enzyme assays for IC50 determinations were performed in 96-well filter plates. IC50 is the inhibitor concentration which inhibits 50% of kinase activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM3665(2-{[3-({4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrim...)
Affinity DataIC50: 1.20nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM4595(6-Substituted 4-Anilinoquinazoline 9 | N-{4-[(3-br...)
Affinity DataIC50: 1.20nMpH: 7.4 T: 2°CAssay Description:Enzyme assays for IC50 determinations were performed in 96-well filter plates. IC50 is the inhibitor concentration which inhibits 50% of kinase activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM4790((2E)-N-[4-(3-Bromoanilino)-6-quinazolinyl]-4-oxo-2...)
Affinity DataIC50: 1.20nMpH: 7.4 T: 2°CAssay Description:Enzyme assays for IC50 determinations were performed in 96-well filter plates. IC50 is the inhibitor concentration which inhibits 50% of kinase activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM3673(2-({4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidin...)
Affinity DataIC50: 1.40nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM3674(7-(Methylamino)-4-[(3-methylphenyl)amino]pyrido-[4...)
Affinity DataIC50: 1.40nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM4806(N-[4-(3-Bromoanilino)-6-quinazolinyl]ethylenesulfo...)
Affinity DataIC50: 1.40nMAssay Description:Enzyme assays for IC50 determinations were performed in 96-well filter plates. IC50 is the inhibitor concentration which inhibits 50% of kinase activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM4803((2E)-N-{4-[(3-bromophenyl)amino]pyrido[3,4-d]pyrim...)
Affinity DataIC50: 1.45nMAssay Description:Enzyme assays for IC50 determinations were performed in 96-well filter plates. IC50 is the inhibitor concentration which inhibits 50% of kinase activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM3669(2-({4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidin...)
Affinity DataIC50: 1.5nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM4779(cid_156414 | PD0183805 | CHEMBL545315 | CHEMBL3196...)
Affinity DataIC50: 1.5nMpH: 7.4 T: 2°CAssay Description:Enzyme assays for IC50 determinations were performed in 96-well filter plates. IC50 is the inhibitor concentration which inhibits 50% of kinase activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM4793(ethyl (2E)-3-({4-[(3-bromophenyl)amino]pyrido[3,4-...)
Affinity DataIC50: 1.5nMAssay Description:Enzyme assays for IC50 determinations were performed in 96-well filter plates. IC50 is the inhibitor concentration which inhibits 50% of kinase activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM3631(5-[(3-Bromophenyl)amino]-1-(2,3-dihydroxypropyl)-p...)
Affinity DataIC50: 1.60nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM4781(N-{4-[(3-bromophenyl)amino]pyrido[3,4-d]pyrimidin-...)
Affinity DataIC50: 1.60nMpH: 7.4 T: 2°CAssay Description:Enzyme assays for IC50 determinations were performed in 96-well filter plates. IC50 is the inhibitor concentration which inhibits 50% of kinase activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM4788(N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}buta-2,...)
Affinity DataIC50: 1.60nMpH: 7.4 T: 2°CAssay Description:Enzyme assays for IC50 determinations were performed in 96-well filter plates. IC50 is the inhibitor concentration which inhibits 50% of kinase activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM4786((2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4...)
Affinity DataIC50: 1.75nMpH: 7.4 T: 2°CAssay Description:Enzyme assays for IC50 determinations were performed in 96-well filter plates. IC50 is the inhibitor concentration which inhibits 50% of kinase activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM3660(4-N-(3-bromophenyl)-7-N-[3-(morpholin-4-yl)propyl]...)
Affinity DataIC50: 1.90nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM4797(3-(dimethylamino)propyl (2E)-3-({4-[(3-bromophenyl...)
Affinity DataIC50: 2.40nMAssay Description:Enzyme assays for IC50 determinations were performed in 96-well filter plates. IC50 is the inhibitor concentration which inhibits 50% of kinase activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM3638(N-(3-bromophenyl)-6-[(dimethylamino)methyl]-8H-pyr...)
Affinity DataIC50: 2.60nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2005
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM3647(2-({4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidin...)
Affinity DataIC50: 2.60nMpH: 7.4 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2005
Entry Details Article
PubMed
Displayed 1 to 50 (of 131 total ) | Next | Last >>
Jump to: